Trials / Completed
CompletedNCT06590870
Intranasal Fentanyl in Preterm Infants Undergoing Peripherally Inserted Central Catheter Placement
Intranasal Fentanyl for Procedural Analgesia in Preterm Infants Undergoing Peripherally Inserted Central Catheter Placement (INFENT PICC): a Feasibility Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Mount Sinai Hospital, Canada · Academic / Other
- Sex
- All
- Age
- 0 Years – 1 Year
- Healthy volunteers
- Not accepted
Summary
The purpose of this feasibility clinical trial is to explore the role of intranasal fentanyl for pain associated with PICC placement in preterm infants. The primary goals are identifying whether enough infants join the study and complete the study procedures.
Detailed description
Infants admitted to the neonatal intensive care unit (NICU) are subjected to multiple painful procedures as part of clinical care. It is established that early and repeated exposure to pain is associated with negative consequences. However, pain management strategies continue to be underutilized in NICUs worldwide. Placement of a PICC is a clinically essential painful procedure in infants requiring prolonged intravenous access. The procedure can cause moderate to severe pain. To date, the optimal medication for procedural analgesia during PICC placement is not known. Intranasal fentanyl has emerged as an option for pain management in infants admitted to the NICU. In preparation for a future definitive clinical trial, this is a feasibility clinical trial exploring the role of intranasal fentanyl for procedural analgesia in preterm infants undergoing PICC placement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fentanyl | The fentanyl solution for administration will be prepared by diluting 2 mL of fentanyl 50 µg/mL with 8 mL of normal saline (bacteriostatic 0.9% sodium chloride) for a fentanyl solution of 10 µg/mL. |
| DRUG | Normal saline | The normal saline solution for administration will be bacteriostatic 0.9% sodium chloride. |
Timeline
- Start date
- 2024-08-09
- Primary completion
- 2025-02-09
- Completion
- 2025-02-09
- First posted
- 2024-09-19
- Last updated
- 2025-02-20
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06590870. Inclusion in this directory is not an endorsement.